Related Experiment Video
Updated: Jun 25, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Effectiveness of tacrolimus in high-risk limbal allo-graft transplantation
F Nilüfer Yalçindag1, Osman Incel, Ozden Ozdemir
1Ankara University Faculty of Medicine, Ophthalmology Department, Ankara, Turkey. yalcinda@medicine.ankara.edu.tr
Insights
Systemic tacrolimus effectively prevented rejection in high-risk limbal grafts for ocular surface reconstruction. This study shows tacrolimus is a safe and successful immunosuppression option for these challenging cases.
Area of Science:
- Ophthalmology
- Immunosuppression
- Regenerative Medicine
Background:
- Severe limbal stem cell deficiency poses challenges for ocular surface reconstruction.
- Allograft rejection is a significant risk in limbal transplantation.
- Effective immunosuppression is crucial for graft survival.
Purpose of the Study:
- To evaluate the efficacy and safety of systemic tacrolimus.
- To prevent allograft rejection in high-risk allo-limbal grafts.
- To assess tacrolimus as an immunosuppressive agent for ocular surface reconstruction.
Main Methods:
- Included six patients with severe limbal stem cell deficiency undergoing allo-limbal grafts.
- Administered oral tacrolimus (0.1 mg/kg/day) starting 3 days pre-surgery.
- Utilized systemic tacrolimus for immunosuppression during ocular surface reconstruction.
Main Results:
- Successful outcomes were achieved in limbal allograft transplantation.
- Systemic tacrolimus demonstrated efficacy in preventing graft rejection.
- The treatment was well-tolerated, indicating a favorable safety profile.
Conclusions:
- Systemic tacrolimus is an effective immunosuppressive strategy for high-risk limbal allografts.
- Tacrolimus facilitates successful ocular surface reconstruction in severe limbal stem cell deficiency.
- This approach offers a promising solution for preventing graft rejection.
Abstract:
We evaluated the efficacy and safety of tacrolimus in prevention of allograft rejection in high-risk allo-limbal grafts. Six eyes of six patients with severe limbal stem cell deficiency were included. All patients were started 0.1 mg x kg 1 x day(-1) tacrolimus orally 3 days before the surgery. Limbal allo-graft transplantation for ocular surface reconstruction had a successful outcome with using systemic tacrolimus for immunosuppression.